Equity and capacity to benefit from early access to medicines schemes
Open Access
- 10 April 2025
- journal article
- review article
- Published by Springer Nature in International Journal for Equity in Health
- Vol. 24 (1) , 1-7
Abstract
Many diseases, especially rare ones, have not gained the attention or support needed to attract dedicated research interest to be able to develop successful medicines. There is, thus, a significant unmet clinical need, not all of which is (or indeed can be) addressed through the evaluation of investigational treatments introduced within the confines of clinical trials. People with severe life-threatening conditions who are not eligible to participate in any ongoing clinical trials may be able to try investigational medicines through schemes facilitating early use of or expanded access to innovative medicines. Here, we focus on the issue of equity in such programmes. Standard metrics of clinical need which inform operational decisions about equity in resource allocation primarily rely on social goods which have already been evaluated, providing evidence to support the standard assessment of patient ‘capacity to benefit’ from given medical interventions. Notions of equity have only relatively recently been discussed within research and innovation generally and within the ethics of clinical trials in particular. Considerations of equity, however, require an overview of all these different patient pathways. We suggest that a new formal method to assess eligibility for early use of or expanded access to innovative medicines be used to capture both the severity of the condition and capacity for scientific or social value alongside clinical trials.Keywords
Funding Information
- AHRC IAA strategic award
This publication has 32 references indexed in Scilit:
- Addressing health inequalities in Europe: key messages from the Joint Action Health Equity Europe (JAHEE)Archives of Public Health, 2023
- An 8-Factor Regulatory Framework to Facilitate Patient Compassionate Use AccessJAMA Health Forum, 2022
- Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)Journal of Clinical Medicine, 2022
- Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer centerPLOS ONE, 2021
- The impact of early phase price agreements on prices of orphan drugsBMC Health Services Research, 2021
- Does free-market capitalism drive unequal access to health? An empirical analysis, 1970–2015Global Public Health, 2020
- Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use ProgramsJAMA Network Open, 2018
- Considerations and guidance in designing equity-relevant clinical trialsInternational Journal for Equity in Health, 2017
- Overview of FDA’s Expanded Access Program for Investigational DrugsTherapeutic Innovation & Regulatory Science, 2017
- Ethical considerations of experimental interventions in the Ebola outbreakThe Lancet, 2014